PMID- 37102080
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230428
IS  - 1658-3612 (Electronic)
IS  - 1658-3612 (Linking)
VI  - 18
IP  - 2
DP  - 2023 Apr
TI  - Effect of Allium sativum and Olea europaea on serum lipids in patients with 
      diabetes mellitus.
PG  - 420-426
LID - 10.1016/j.jtumed.2022.09.007 [doi]
AB  - OBJECTIVE: This study was designed to assess the effects of a combination of 
      Allium sativum and Olea europaea oil on disturbed lipid profiles in patients with 
      type 2 diabetes mellitus (T2DM). METHODS: This randomized control trial (RCT) 
      involved 160 patients of either sex (aged 40-60 years) with T2DM and 
      dyslipidemia, and were equally divided into two groups. Group A patients received 
      hypoglycemic and lipid lowering agents (Tab glimepiride 2 mg + metformin HCl 500 
      mg and Tab rosuvastatin 10 mg once a day orally). Patients in group B were given 
      the same allopathic drugs as group A, in combination with A. sativum and 
      O. europaea oil over a period of 6 months. Blood samples were taken at three 
      stages of the study to allow the analysis of lipid profiles. RESULTS: Analysis 
      showed that after 3 and 6 months of treatment, the mean levels of serum 
      cholesterol, triglycerides (TGs) and low-density lipoprotein (LDL) were reduced 
      in both groups and that there was a highly significant (P < 0.001) decline in 
      group B when compared to group A. High-density lipoprotein (HDL) levels increased 
      in both groups but there was a significant (P < 0.05) increase in the group B 
      when compared to group A. The percentage reduction was highest at 6 months of 
      treatment for cholesterol, TGs, LDL and HDL in group B (41.5%, 45.9%, 60.4% and 
      58.1%, respectively). CONCLUSION: The antihyperlipidemic activity observed may be 
      due to the presence of antioxidants in the test substances. Further studies 
      should be conducted with a larger sample size in order to further evaluate the 
      role of A. sativum powder and O. europaea oil in patients with T2DM with 
      dyslipidemia.
CI  - (c) 2022 [The Author/The Authors].
FAU - Memon, Ali Raza
AU  - Memon AR
AD  - Department of Biochemistry, Liaquat University of Medical & Health Sciences, 
      Jamshoro, Pakistan.
FAU - Rajput, Muhammad Ali
AU  - Rajput MA
AD  - Department of Pharmacology, Multan Medical & Dental College, Multan, Pakistan.
AD  - Department of Pharmacology, College of Medicine, Gulf Medical University, Ajman, 
      United Arab Emirates.
FAU - Rizwan, Fazeela
AU  - Rizwan F
AD  - Department of Pharmacology, Liaquat University of Medical & Health Sciences, 
      Jamshoro, Pakistan.
FAU - Akram, Muhammad
AU  - Akram M
AD  - Department of Biochemistry, Liaquat University of Medical & Health Sciences, 
      Jamshoro, Pakistan.
FAU - Rizwan, Muhammad
AU  - Rizwan M
AD  - Department of Pharmacology, Liaquat University of Medical & Health Sciences, 
      Jamshoro, Pakistan.
FAU - Iqbal, Zeemal
AU  - Iqbal Z
AD  - Department of Pharmacology, Multan Medical & Dental College, Multan, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20221008
PL  - Saudi Arabia
TA  - J Taibah Univ Med Sci
JT  - Journal of Taibah University Medical Sciences
JID - 101621911
PMC - PMC10124115
OTO - NOTNLM
OT  - Allium sativum
OT  - Diabetes mellitus
OT  - Dyslipidemia
OT  - Lipid profile
OT  - Olea europaea
EDAT- 2023/04/27 06:42
MHDA- 2023/04/27 06:43
PMCR- 2022/10/08
CRDT- 2023/04/27 02:15
PHST- 2022/05/31 00:00 [received]
PHST- 2022/08/13 00:00 [revised]
PHST- 2022/09/22 00:00 [accepted]
PHST- 2023/04/27 06:43 [medline]
PHST- 2023/04/27 06:42 [pubmed]
PHST- 2023/04/27 02:15 [entrez]
PHST- 2022/10/08 00:00 [pmc-release]
AID - S1658-3612(22)00176-7 [pii]
AID - 10.1016/j.jtumed.2022.09.007 [doi]
PST - epublish
SO  - J Taibah Univ Med Sci. 2022 Oct 8;18(2):420-426. doi: 
      10.1016/j.jtumed.2022.09.007. eCollection 2023 Apr.